Gabapentin alleviates affective pain after traumatic nerve injury

NeuroReport

Volumn 26, Issue 9, 2015, Pages 522-527

  Griggs, Ryan B ^a   Bardo, Michael T ^b   Taylor, Bradley K ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Affective; conditioned place preference; gabapentin; neuropathic; pain; spared nerve injury

Indexed keywords

GABAPENTIN; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

AFFECTIVE PAIN; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONING; CONTROLLED STUDY; HYPERSENSITIVITY; LOCOMOTION; MALE; NERVE INJURY; NONHUMAN; PAIN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; SPARED NERVE INJURY; AFFECT; ANIMAL; COMPLICATION; DRUG EFFECTS; INJURIES; NEURALGIA; PERIPHERAL NERVE INJURIES; SCIATIC NERVE; SPRAGUE DAWLEY RAT;

AFFECT; AMINES; ANALGESICS; ANIMALS; CONDITIONING (PSYCHOLOGY); CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; MALE; NEURALGIA; PERIPHERAL NERVE INJURIES; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE;

EID: 84930589725     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000382     Document Type: Article

References (25)

1. Sufka KJ. Conditioned place preference paradigm: a novel approach for analgesic drug assessment against chronic pain. Pain 1994; 58:355-366.
2. King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, et al. Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci 2009; 12:1364-1366.
3. King T, Porreca F Preclinical assessment of pain: improving models in discovery research. In: Taylor BK, Finn DP, editors. Behavioral Neurobiology of Chronic Pain. Springer Berlin Heidelberg; 2014. Vol. 20 pp. 1-20.
4. Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007; 12:227-462.
5. Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward Psychopharmacology (Berl) 2000; 153:31-43.
6. Attal N, Cruccu G, Baron R, Haanpaä M, Hansson P, Jensen TS, Nurmikko T. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17:1113-e88.
7. Lemos L, Alegria C, Oliveira J, Machado A, Oliveira P, Almeida A. Pharmacological versus microvascular decompression approaches for the treatment of trigeminal neuralgia: clinical outcomes and direct costs. J Pain Res 2011; 4:233-244.
8. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280:1837-1842.
9. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22:2909-2917.
10. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280:1831-1836.
11. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7:573-583.
12. Park HJ, Stokes JA, Pirie E, Skahen J, Shtaerman Y, Yaksh TL. Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept. Anesth Analg 2013; 116:224-231.
13. Wagner K, Yang J, Inceoglu B, Hammock BD. Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. J Pain 2014; 15:907-914.
14. Xie JY, Qu C, Patwardhan A, Ossipov MH, Navratilova E, Becerra L, et al. Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. Pain 2014; 155:1659-1666.
15. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000; 87:149-158.
16. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63.
17. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20:441-462.
18. Morgenweck J, Griggs RB, Donahue RR, Zadina JE, Taylor BK. PPARgamma activation blocks development and reduces established neuropathic pain in rats. Neuropharmacology 2013; 70:236-246.
19. Wei H, Viisanen H, Amorim D, Koivisto A, Pertovaara A. Dissociated modulation of conditioned place-preference and mechanical hypersensitivity by a TRPA1 channel antagonist in peripheral neuropathy. Pharmacol Biochem Behav 2013; 104:90-96.
20. Cunningham CL, Ferree NK, Howard MA. Apparatus bias and place conditioning with ethanol in mice. Psychopharmacology (Berl) 2003; 170:409-422.
21. Hama AT, Borsook D. The effect of antinociceptive drugs tested at different times after nerve injury in rats. Anesth Analg 2005; 101:175-179.
22. Brederson JD, Kym PR, Szallasi A. Targeting TRP channels for pain relief. Eur J Pharmacol 2013; 716:61-76.
23. Okun A, DeFelice M, Eyde N, Ren J, Mercado R, King T, Porreca F. Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents. Mol Pain 2011; 7:4.
24. Okun A, Liu P, Davis P, Ren J, Remeniuk B, Brion T, et al. Afferent drive elicits ongoing pain in a model of advanced osteoarthritis. Pain 2012; 153:924-933.
25. Gordh TE, Stubhaug A, Jensen TS, Arnèr S, Biber B, Boivie J, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 2008; 138:255-266.